Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor

被引:2
|
作者
Vonk, Steffie E. M. [1 ]
Altenburg, Josje [2 ]
Mathot, Ron A. A. [1 ]
Kemper, E. Marleen [1 ,3 ]
机构
[1] Univ Amsterdam, Dept Hosp Pharm & Clin Pharmacol, Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Dept Pulm Med, Amsterdam UMC, Meibergdreef 9, Amsterdam, Netherlands
[3] Univ Amsterdam, Dept Vasc Med, Amsterdam UMC, Amsterdam, Netherlands
关键词
Elexacaftor-tezacaftor-ivacaftor; Therapeutic drug monitoring; Area under the curve; Trough concentration; CFTR modulators;
D O I
10.1016/j.jcf.2024.03.010
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Therapeutic drug monitoring (TDM) of elexacaftor, tezacaftor, ivacaftor (ETI) could be a useful tool to increase efficacy and decrease the risk of adverse effects in people with Cystic Fibrosis (pwCF). It is however unclear whether drug exposure should be monitored by assessment of trough (C-min) levels or determination of the area under the curve (AUC). Hence, in this study the correlation between measured C min concentration and AUC was evaluated. Serial plasma samples, including C-min , were drawn after administration of ETI in order to calculate the AUC and assess the correlation between the two parameters. A linear correlation between C- min and AUC 0-24h was found, with Pearson's r correlation coefficients of 0.963, 0.908 and 0.860 for elexacaftor, tezacaftor and ivacaftor, respectively. Exposure of ETI may be monitored by assessment of C( min )levels.
引用
收藏
页码:1007 / 1009
页数:3
相关论文
共 50 条
  • [31] Early insurance coverage of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
    Anderson, Ashlee
    McCoy, Lindsey
    Pettit, Rebecca S.
    Wright, Brittany A.
    Lubsch, Lisa
    PEDIATRIC PULMONOLOGY, 2021, 56 (12) : 4053 - 4054
  • [32] Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy
    Heo, Suyeon
    Young, David C.
    Safirstein, Julie
    Bourque, Brian
    Antell, Martine H.
    Diloreto, Stefanie
    Rotolo, Shannon M.
    JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (02) : 339 - 343
  • [33] Management of neuropsychiatric symptoms in adults treated with elexacaftor/tezacaftor/ivacaftor
    Baroud, Evelyne
    Chaudhary, Nivedita
    Georgiopoulos, Anna M.
    PEDIATRIC PULMONOLOGY, 2023, 58 (07) : 1920 - 1930
  • [34] INITIATION OF ELEXACAFTOR-TEZACAFTOR-IVACAFTOR LEADING TO LUNG TRANSPLANTATION
    Homan, Travis
    Link, Stephanie
    Barrios, Christopher
    CHEST, 2020, 158 (04) : 1367A - 1367A
  • [35] Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations
    Fainardi, Valentina
    Cresta, Federico
    Sorio, Claudio
    Melotti, Paola
    Pesce, Emanuela
    Deolmi, Michela
    Longo, Francesco
    Karina, Kleinfelder
    Esposito, Susanna
    Pisi, Giovanna
    PEDIATRIC PULMONOLOGY, 2024, 59 (12) : 3383 - 3390
  • [36] CLINICAL EFFECTIVENESS OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR: THE LONGITUDINAL PROMISE STUDY
    Nichols, D. P.
    Paynter, A.
    Kirby, S.
    VanDalfsen, J.
    Khan, U.
    Heltshe, S. L.
    Donaldson, S. H.
    Frederick, C. A.
    Freedman, S.
    Gelfond, D.
    Hoffman, L.
    Kelly, A.
    Narkewicz, M. R.
    Sagel, S.
    Schwarzenberg, S.
    Singh, P.
    Solomon, G. M.
    Stalvey, M. S.
    Clancy, J. P.
    Rowe, S.
    PEDIATRIC PULMONOLOGY, 2020, 55 : S210 - S211
  • [38] Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
    Zhang, Lijia
    Albon, Dana
    Jones, Marieke
    Bruschwein, Heather
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2022, 16
  • [40] Effect of elexacaftor/tezacaftor/ivacaftor on airway and systemic inflammation in cystic fibrosis
    Casey, Michelle
    Gabillard-Lefort, Claudie
    McElvaney, Oisin F.
    McElvaney, Oliver J.
    Carroll, Tomas
    Heeney, Ronan C.
    Gunaratnam, Cedric
    Reeves, Emer P.
    Murphy, Mark P.
    McElvaney, Noel G.
    THORAX, 2023, 78 (08) : 835 - 839